Document:

exv10w3

Exhibit 10.3

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

EXCLUSIVE LICENSE AGREEMENT FOR TUSCHL II UNITED STATES

PATENTS AND PATENT APPLICATIONS

     This Exclusive License Agreement for Tuschl II United States Patents and Patent Applications
(“Agreement”) is made as of March 14, 2011 (“Effective Date”), by and between Alnylam
Pharmaceuticals, Inc. (“Alnylam”) and University of Massachusetts (“UMass”).

     This Agreement is made with respect to the following recitals:

     WHEREAS, Max-Planck-Gesellschaft zur Föerderung der Wissenschaften e.V. (“Max-Planck”), is an
owner of rights in and to the patents and patent applications defined herein as the US Tuschl II
Patent Family;

     WHEREAS, pursuant to that certain Assignment Agreement made and entered into as of March 14,
2011, UMass has become a co-owner of the US Tuschl II Patent Family;

     WHEREAS, UMass has the right to grant licenses under the US Tuschl II Patent Family;

     WHEREAS, Alnylam desires to obtain a license with the right to grant sublicenses under the US
Tuschl II Patent Family, and UMass desires to grant such license subject to the conditions set
forth herein;

     NOW, THEREFORE, Alnylam and UMass hereby agree as follows:

1. Definitions. The following words and phrases shall have the meanings set forth below
solely for purposes of this Agreement.

     1.1. “Affiliate” shall mean any corporation or other business entity that now or in the future
directly or indirectly controls, is controlled by, or is under common control with, a Party or a
Third Party (as the case may be under this Agreement). Control means direct or indirect ownership
of, or other beneficial interest in, fifty percent (50%) or more of the voting stock, other voting
interest, or income of a corporation or other business entity, or possession of the power to elect
or appoint fifty percent (50%) or more of the members of the governing body of the corporation or
other business entity. A corporation or other business entity shall be an Affiliate only during
such period of time that it meets the definition set forth in this Section 1.1.

     1.2. “Collaboration Partner” shall mean an entity involved in a bona fide collaboration with
Merck or any of Merck’s Affiliates sublicensed in accordance herewith. A bona fide collaboration
shall mean a collaboration with Merck or any of its Affiliates sublicensed in accordance herewith,
where such collaboration is entered into after Merck’s commencement of GLP toxicology testing of
the Licensed Product required for the filing of an Investigational New Drug Application and
involves the development of a Licensed Product in the Field, in which Merck plays an integral role
in the experimentation and a dominant or co-equal role in the decision-making, relating to the
development of such Licensed Product in the Field. Merck’s or any of its properly-sublicensed
Affiliates’ experimentation relating to the discovery and development of a Licensed Product in the

 

 

Field prior to the commencement of a collaboration shall be deemed to have been conducted in
the course of the collaboration for purposes of determining whether the collaboration constitutes a
bona fide collaboration.

     1.3. “Confidentiality Agreement” shall mean a document in the form attached as Exhibit B
hereto.

     1.4. “Distributor” shall mean an entity that purchases Licensed Products (whether in packaged
form or bulk form) from Merck, one of its Affiliates, or a Collaboration Partner, and resells such
Licensed Products to Third Parties in a manner consistent with normal trade practices in the
pharmaceutical industry.

     1.5. “Excluded Targets” shall mean any Target for which Alnylam has, prior to the Effective
Date, granted a Third Party exclusive rights under the US Tuschl II Patent Family, unless such
Target has ceased to be an Excluded Target pursuant to Section 2.2 hereof.

     1.6. “Field” shall mean all uses other than the commercial sale or use as a research reagent,
including in a kit format, for research or educational purposes, including without limitation,

	 	(i)	 	internal and collaborative use;
	 
	 	(ii)	 	all therapeutic and prophylactic uses; and
	 
	 	(iii)	 	diagnostic uses for purposes of therapeutic monitoring, but
excluding all other diagnostic uses, specifically including human and
veterinary diseases, for all indications.

     1.7. “Gatekeeper” shall mean an independent attorney, not employed by Alnylam, registered to
practice before the United States Patent and Trademark Office who shall be mutually agreed upon by
UMass and Alnylam, and who shall be bound by the Confidentiality Agreement and perform the services
identified in Section 2.3 of this Agreement.

     1.8. “Licensed Product” shall mean any product or part thereof in the Field, the manufacture,
use or sale of which would, absent the license granted hereunder, infringe one or more claims of an
issued patent in the US Tuschl II Patent Family.

     1.9. “Merck” shall mean Merck & Co., Inc.

     1.10. “Merck License Agreement” shall mean a non-exclusive license agreement entered into by
Merck under the terms and restrictions provided for in Section 2.2 of this Agreement.

     1.11. “Party” shall mean Alnylam or UMass, and when used in the plural shall mean both all of
them.

- 2 -

 

     1.12. “Sublicensee” shall mean any corporation, firm, partnership, limited liability company,
or other legal entity or business association other than an Affiliate of Alnylam that sells or
intends to commercialize Licensed Products under a sublicense from Alnylam to develop, make, use
and sell Licensed Products. Sublicensee shall not include a distributor. For the purpose of this
Agreement, Sublicensee shall also include the assignees of Alnylam to which Alnylam has
sub-assigned its ownership position in the Tuschl II United States Patents and Patent Applications
in certain countries.

     1.13. “Target” shall mean [**].

     1.14. “Term” shall mean the period commencing on the Effective Date and concluding on the
expiration or abandonment of all issued patents and filed patent applications in the US Tuschl II
Patent Family.

     1.15. “Third Party” shall mean any corporation, firm, partnership, limited liability company,
or other legal entity or business association other than Alnylam, an Affiliate of Alnylam, or a
Sublicensee.

     1.16. “US Tuschl I Patent Family” shall mean any and all patents issued by, and patent
applications filed in, the USPTO as set forth in the attached Exhibit C, entitled “RNA
sequence-specific mediators of RNA interference,” naming as inventors Thomas Tuschl, David P.
Bartel, Phillip A. Sharp, and Phillip D. Zamore, and any divisionals, continuations,
continuation-in-part applications thereof, requests for continued examination, reissues or
reexaminations of any of the foregoing filed in the USPTO.

     1.17. “US Tuschl II Patent” shall mean any patent within the scope of rights covered by
Section 1.18 that is issued by the United States Patent and Trademark Office.

     1.18. “US Tuschl II Patent Family” shall mean any and all patents issued by, and patent
applications filed, in the USPTO as set forth in the attached Exhibit A, entitled “RNA Interference
Mediating Small RNA Molecules,” naming as inventors by Thomas Tuschl, Sayda Elbashir, and Winfried
Lendeckel, and any divisionals, continuations, continuation-in-part applications thereof, requests
for continued examination, reissues or reexaminations of any of the foregoing filed in the USPTO.

2. Grant of Rights.

     2.1. Exclusive License. Except as expressly set forth in Section 2.2, UMass grants to
Alnylam for the Term an exclusive, unrestricted, royalty-free license, with the right to grant
sublicenses, under the US Tuschl II Patent Family including without limitation the right to make,
have made, sell, have sold, offer for sale, import and use any Licensed Product.

     2.2. Merck License Agreement. Notwithstanding the license set forth in Section 2.1,
UMass reserves the right to convey an option (and corresponding licenses) to Merck (and to no other
person or entity) to acquire from UMass one or more non-exclusive licenses to make, have made,
sell, have sold, offer for sale, import and use any Licensed Product, except with respect to
Excluded Targets, under the US Tuschl II Patent Family, provided that the agreement conveying the
option and any agreement granting any such license shall

- 3 -

 

include provisions to the effect that (i) Merck shall have no right to grant any sublicenses,
except to (a) an Affiliate (which sublicense shall automatically terminate at the time that the
entity to which the sublicense was granted ceases to be an Affiliate of Merck); and (b) a
Collaboration Partner, Distributor, or a contractor working under the direction of Merck or a Merck
Affiliate to the extent such contractor assists in performing the activities licensed hereunder,
and in such cases only with respect to the specific Licensed Product that is the subject of the
particular collaboration, distribution or services agreement; (ii) the option agreement and all
licenses shall automatically terminate if Merck files a legal proceeding in the USPTO, a United
States court, or an arbitral forum, challenging the validity, enforceability or inventorship of any
application or patent in the US Tuschl II Patent Family, except if Merck is sued for infringement
of a US Tuschl II Patent; and (iii) the license cannot be assigned except to an Affiliate or in
connection with a merger, acquisition, or sale of all or substantially all of the assets of Merck
or an Affiliate relating to the subject matter of the US Tuschl II Patent Family, which sale
includes the assignment of the License Agreement dated September 8, 2003, between UMass and Sirna
Therapeutics, Inc. Nothing contained in this Section 2.2 shall be construed to prevent Merck from
asserting non-infringement as a defense in any legal proceeding involving a patent or application
in the US Tuschl II Patent Family, or to assert any defense in a legal proceeding outside the
United States involving a patent or application that is not a member of the US Tuschl II Patent
Family. UMass acknowledges and agrees that (a) it shall have no right to grant to Merck any rights
under the US Tuschl II Patent Family with respect to any Excluded Targets, and (b) any
non-exclusive license granted to Merck pursuant to this Section 2.2 shall expressly provide that
Merck is prohibited from granting any sublicense, covenant not to sue, or freedom to operate under
any application or patent in the US Tuschl II Patent Family except as set forth in clause (i)
above. Alnylam represents and warrants that, as of the Effective Date, there are [**] Excluded
Targets. Alnylam shall allow UMass to designate a single outside attorney (the “UMass Attorney”)
who agrees to be bound by the Confidentiality Agreement to inspect at Alnylam’s offices, at a
reasonable time and with reasonable advance notice, documents sufficient to confirm that, as of the
Effective Date, there are [**] Excluded Targets. Alnylam agrees that, if at any time after the
Effective Date, a Target ceases to be subject to exclusive rights granted to another entity under
the US Tuschl II Patent Family, then such Target shall no longer be an Excluded Target.

     2.3. Provisions Concerning Excluded Targets. Alnylam shall provide the Gatekeeper
with a certified list of Excluded Targets within [**] of the Effective Date. The Gatekeeper shall
maintain such list in a secure location during the Term of this Agreement. Alnylam shall update
the list of Excluded Targets during the Term of the Agreement by promptly informing the Gatekeeper
when a Target has been removed from the list. Merck may, from time to time, provide to the
Gatekeeper in confidence a list of proposed Targets. Within [**] following the Gatekeeper’s
receipt of such list from Merck, the Gatekeeper shall notify Merck in writing which, if any, of the
Targets identified on such list are Excluded Targets, and hence would be excluded from the Merck
License Agreement. If the Gatekeeper has questions as to whether a proposed Target is an Excluded
Target, the Gatekeeper may, in his or her sole discretion, pose appropriate scientific questions to
an independent expert, which expert shall first enter into and be bound by the Confidentiality
Agreement. In the event that the Gatekeeper informs Merck that any proposed Target is an Excluded
Target, the UMass Attorney may thereafter inspect all documents on which the Gatekeeper relied in
determining that the proposed Target is an Excluded Target, and the

- 4 -

 

Gatekeeper shall disclose to the UMass Attorney any advice received from any independent
scientific expert. If wishes to exercise its option to enter into a Merck License Agreement
provided for in (and subject to the terms and restrictions of) Section 2.2 above, UMass, Merck,
Alnylam and the Gatekeeper shall each enter into the Confidentiality Agreement. (i) In the event
that the Merck License Agreement is to cover all Targets except Excluded Targets, the Gatekeeper
shall provide UMass with the list of Excluded Targets within [**] of receiving notice from UMass of
Merck’s request to exercise its option to enter into a Merck License Agreement and the
Confidentiality Agreement executed by authorized representatives of UMass and Merck. The list of
Excluded Targets shall be attached as an exhibit to the Merck License Agreement, which shall
expressly provide that no rights are granted with respect to all such Excluded Targets (as required
by Section 2.2) and which list shall remain subject to the terms of the Confidentiality Agreement.
(ii) In the event that the Merck License Agreement is to be limited to a particular Target or
Targets only, UMass shall thereupon provide to the Gatekeeper in confidence a list of the proposed
Targets to be covered by the Merck License Agreement. Within [**] following the Gatekeeper’s
receipt of such list from UMass, the Gatekeeper shall notify UMass in writing which, if any, of the
Targets identified on such list are Excluded Targets, and hence must be excluded from the Merck
License Agreement. Such writing shall be subject to the terms of the Confidentiality Agreement.
If the Gatekeeper has any questions as to whether a proposed Target is an Excluded Target, the
Gatekeeper may, in his or her sole discretion, pose appropriate scientific questions to an
independent expert, which expert shall first enter into and be bound by the Confidentiality
Agreement. In the event that the Gatekeeper informs Merck that any proposed Target is an Excluded
Target, the UMass Attorney may thereafter inspect all documents on which the Gatekeeper relied in
determining that the proposed Target is an Excluded Target, and the Gatekeeper shall disclose to
the UMass Attorney any advice received from any independent scientific expert. UMass may grant
Merck a license with respect to any Targets not identified by the Gatekeeper as Excluded Targets,
subject to the terms and restrictions of Section 2.2.

     2.4. Retained Research Rights. UMass shall retain the right to practice the
inventions claimed in the US Tuschl II Patent Family for research, teaching, education,
non-commercial collaboration and publication purposes. Alnylam acknowledges that the U.S. federal
government retains a royalty-free, non-exclusive, non-transferable license to practice any
government-funded invention claimed in any patent or application in the US Tuschl II Patent Family
for government purposes.

     2.5. No Further Conveyances of Rights. (a) Except as expressly set forth in Section
2.2, UMass covenants and agrees (i) not to dedicate to the public nor to convey to any entity
whatsoever, including to any of its or their Affiliates or other Third Parties, whether by
assignment, license or otherwise, any interest in the US Tuschl II Patent Family; and (ii) not to
make any representation in any form or manner that any patent application or patent in the US
Tuschl II Patent Family may be used for research purposes other than as expressly agreed to
pursuant to the September 2001 Joint Invention and Joint Marketing Agreement. (b) Under no
circumstance shall UMass disclaim or otherwise relinquish ownership of any US Tuschl II Patent
without the prior written consent of Max Planck. In the event that UMass does disclaim or otherwise
relinquish its ownership interest in any US Tuschl II Patent, in addition to any other rights and
remedies available to the Parties, UMass shall be deemed to have disclaimed and relinquished its
ownership interest in every patent

- 5 -

 

and application in the US Tuschl II Patent Family and in every patent and application in the
US Tuschl I Patent Family such that common ownership is maintained between the US Tuschl I Patent
Family and the US Tuschl II Patent Family.

     2.6. No Additional Rights. Nothing in this Agreement shall be construed to confer any
rights upon Alnylam by implication, estoppel, or otherwise as to any intellectual property rights,
including without limitation patents and patent applications, trademarks, copyrights and know-how,
of UMass other than the US Tuschl II Patent Family, regardless of whether such intellectual
property rights shall be dominant or subordinate to any patent application or patent in the US
Tuschl II Patent Family.

3. Patent Enforcement.

     3.1. Notice. Each Party shall notify the other Party promptly in writing of any
infringement of any US Tuschl II Patent that becomes known to any of them, including without
limitation the receipt of any Paragraph IV notice letter under the Drug Price Competition and
Patent Term Restoration Act of 1984 (commonly referred to as the Hatch-Waxman Act). In no event
shall such notice be given more than [**] after learning of any infringement.

     3.2. Control of Patent Enforcement. Alnylam shall have the right to bring suit for
infringement of any claim in any US Tuschl II Patent, to enjoin infringement, to collect damages,
profits and awards of whatever nature recoverable for such infringement, to defend against any
challenge to validity of such patent, and to pursue any such litigation until a final judgment,
from which no further appeal may be taken and no further review may be sought.

          3.2.1. Upon reasonable prior notice, Alnylam may join UMass as a party if necessary in any
such litigation brought in the United States against a for-profit commercial entity (the US
Commercial Infringement Litigation”), provided that the complaint satisfies all pleading
obligations and the requirements of Rule 11 of the Federal Rules of Civil Procedure. Alnylam shall
select counsel to represent Alnylam and UMass in connection with such US Commercial Infringement
litigation, provided that UMass shall have a right of prior approval with respect to counsel for
UMass, such approval not to be unreasonably withheld or delayed. Counsel representing UMass must
be appointed a Special Assistant Attorney General and comply with the guidelines of the
Massachusetts Attorney General with respect to that appointment. Alnylam shall have control over
all decisions in, and any settlement of, any such US Commercial Infringement Litigation, provided
that UMass shall have a right of prior approval over significant litigation decisions concerning,
and settlement of, any non-patent claims or non-patent counterclaims to the extent they affect the
interests of the Commonwealth of Massachusetts, such approval not to be unreasonably withheld or
delayed. Alnylam shall reasonably consult with UMass and keep it informed concerning developments
in the US Commercial Litigation.

          3.2.2. In the event there arises an actual or potential conflict of interest between Alnylam
and UMass with respect to the US Commercial Infringement Litigation such that representation of
UMass by the counsel retained by Alnylam is inappropriate, Alnylam shall not thereafter have
control over decisions in the litigation affecting UMass,

- 6 -

 

and UMass shall be entitled to select its own counsel, which counsel shall be paid for by the
UMass and not by Alnylam. Alnylam shall further obtain the prior consent of UMass to settle such
litigation, which consent shall not be unreasonably withheld.

          3.2.3. Alnylam shall hold UMass harmless from, and indemnify it against, any costs, expenses,
or liability the UMass may incur in connection with any action taken under this Section 3; provided
that Alnylam shall be obligated to reimburse UMass for costs and expenses incurred during the
prosecution or defense of any such litigation only if reasonably incurred by UMass for purposes of
such action.

     3.3. Alnylam Fees. Any and all fees, costs and expenses incurred by Alnylam,
including, without limitation, attorney’s fees, court costs and disbursements, in connection with
any action taken under this Section 3 shall be paid by Alnylam.

     3.4. Cooperation. UMass shall cooperate fully with Alnylam in connection with any
action under this Section 3 and agrees to promptly provide reasonable access to all necessary
documents, information, and persons under its control, and to render reasonable assistance in
response to a request by Alnylam for such assistance, all at Alnylam’s expense.

     3.5. Consent. UMass shall not be entitled to bring a suit for infringement of any US
Tuschl II Patent without the express written consent of Alnylam, which Alnylam may withhold in its
sole discretion.

4. Confidentiality

     4.1. Limitations on Disclosure. The Parties and their counsel shall take reasonable
measures to ensure that the terms of this Exclusive License Agreement remain strictly confidential
and are not disclosed to any third party, except as specifically set forth in Sections 4.2.1
through 4.2.5.

          4.1.1. Pursuant to Order. The terms of this Confidential Settlement Agreement may be
disclosed pursuant to any order or subpoena requiring disclosure in any legal proceeding, but only
so long as the Party that has the disclosure requirement provides the other Parties with written
notice of such requirement not later than [**] after first learning of such order or subpoena.

          4.1.2. Professional Advisers. The terms of this Exclusive License Agreement may be
disclosed to any Party’s attorney, accountant, auditor, or insurer, but only so long as any such
person or entity is informed of this confidentiality provision and agrees in writing to take
reasonable measures to keep the terms of this Exclusive License Agreement strictly confidential and
prevent their disclosure to any third party except as permitted by Sections 4.1.4 and 4.1.5.

          4.1.3. Merck. The terms of this Exclusive License Agreement may be disclosed to
Merck, but only so long as Merck is informed of this confidentiality provision and agrees in
writing to take reasonable measures to keep the terms of this Exclusive License Agreement strictly
confidential and prevent their disclosure to any third party except as permitted by Sections 4.1.4
and 4.1.5.

- 7 -

 

          4.1.4. Required by Law. The terms of this Exclusive License Agreement may be
disclosed as required by law, including but not limited to any disclosure required to be made
pursuant to the reporting obligations applicable to nonprofit corporations or recipients of federal
funds or as required by the Securities and Exchange Commission or other such regulatory
authorities, or as required by the Office of the Attorney General of the Commonwealth of
Massachusetts. Prior to making any such disclosure, the Party intending to make the disclosure
shall provide the other Party with a redacted version of this Exclusive License Agreement to be
disclosed pursuant to this Section 4.1.4 and give the other Party a reasonable opportunity to
object to the content of the redacted document on the ground that it would disclose more
information than authorized by this Section 4.1.4.

          4.1.5. Public Information. Any term of this Confidential Settlement Agreement may be
disclosed publicly only to the extent such term is publicly known or widely disseminated to the
public, other than through the wrongful act of the Party or its Affiliates, prior to the disclosure
by the Party.

5. Miscellaneous Provisions.

          5.1.1. Non-Use of UMass Trademarks. Neither Alnylam nor its Affiliates and
Sublicensees shall use the name of “University of Massachusetts,” or any variation, adaptation, or
abbreviation thereof, or of any of its trustees, officers, faculty, students, employees, or agents,
or any trademark owned by any of them, in any promotional material or other public announcement or
disclosure, without the prior written consent of the UMass or in the case of an individual, the
consent of that individual. The foregoing notwithstanding, Alnylam may state generally that it has
a license from UMass under the US Tuschl II Patent Family, subject only to UMass’s reserved rights
to convey non-exclusive licenses to Merck.

          5.1.2. Termination. This license is non-revocable and cannot be terminated under any
circumstances.

          5.1.3. Limitation of Remedies. IN NO EVENT SHALL THE PARTIES, THEIR TRUSTEES,
DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES, BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY KIND, DIRECT OR INDIRECT, RELATING TO THIS AGREEMENT, INCLUDING ECONOMIC DAMAGES,
ATTORNEYS’ FEES, OR INJURY TO PROPERTY OR LOST PROFITS, REGARDLESS OF WHETHER THE PARTY OR PARTIES
SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE
FOREGOING.

     5.2. Notices. Any notices required or permitted under this Agreement and all
correspondence hereunder shall be in English and in writing, shall specifically refer to this
Agreement, and shall be sent by a method providing confirmation of delivery to the following
addresses or facsimile numbers of the parties:

If to UMass:

Office of Technology Management

University of Massachusetts

- 8 -

 

222 Maple Avenue

Higgins Building, Suite 114

Shrewsbury, MA 01545

Attn: Executive Director

If to Alnylam:

Alnylam Pharmaceuticals, Inc.

300 Third Street

Cambridge, MA 02142

Attn: General Counsel

     5.3. Governing Law. This Agreement shall be construed, governed, interpreted and
applied in accordance with the laws of the Commonwealth of Massachusetts, even if the laws of the
Commonwealth would select a different governing law.

     5.4. Compliance with Laws. Alnylam shall use commercially reasonable efforts to
comply with all local, state, federal, and international laws and regulations relating to the
development, manufacture, use and sale of Licensed Products.

     5.5. Indemnification. Alnylam shall indemnify, defend, and hold harmless UMass and
its trustees, officers, faculty, students, employees, and agents and their respective successors,
heirs and assigns (the “indemnitees”), against any liability, damage, loss, or expense (including
reasonable attorneys’ fees and expenses) incurred by or imposed upon any of the indemnitees in
connection with any claims, suits, actions, demands or judgments arising out of any theory of
liability (including without limitation actions in the form of tort, warranty, or strict liability
and regardless of whether such action has any factual basis) concerning (i) any use of the
inventions claimed in the US Tuschl II Patent Family by Alnylam or its sublicensees, or (ii) any
product, process, or service that is developed, made, used, sold, or performed by Alnylam or its
sublicensees pursuant to any right or license granted to Alnylam under this Agreement. Alnylam
shall obtain and carry in full force and effect commercial general liability insurance, including
product liability and errors and omissions insurance, which shall protect Alnylam and its
indemnitees, including UMass, with respect to events covered by this Section.

     5.6. Integration. This Agreement supersedes all prior written agreements and all
prior written and contemporaneous oral agreements with respect to the subject matter hereof.

     5.7. Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise
modified only by means of a written instrument signed by all parties. Any waiver of any rights or
failure to act in a specific instance shall relate only to such instance and shall not be construed
as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

     5.8. Severability. Should one of the provisions of this Agreement be held void,
invalid or unenforceable, the remaining provisions of this Agreement will not cease to be
effective. The parties shall negotiate in good faith to replace such void, invalid or

- 9 -

 

unenforceable provision by a new provision which reflects, to the extent possible, the
original intent of the parties.

     5.9. Headings. All headings are for convenience only and shall not affect the meaning
of any provision of this Agreement.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives.

ALNYLAM PHARMACEUTICALS, INC.

	 	 	 	 	 	 	 

	 

	 	By:
	 	/s/ Barry Greene
 

	 	 
	 

	 	Its:
	 	President and Chief Operating Officer	 	 

UNIVERSITY OF MASSACHUSETTS

	 	 	 	 	 	 	 

	 

	 	 	 	/s/ James P. McNamara, Ph.D.
 

	 	 
	 

	 	By:
	 	James P. McNamara, Ph.D.	 	 
	 

	 	Its:
	 	Executive Director	 	 
	 

	 	 	 	Office of Technology Management	 	 

- 10 -

 

EXHIBIT A

CONFIDENTIALITY AGREEMENT

     Reference is made to that certain Exclusive License Agreement for Tuschl II United States
Patents and Patent Applications (the “Exclusive License Agreement”) made as of March 14, 2011 by
and between Alnylam Pharmaceuticals, Inc. (“Alnylam”) and University of Massachusetts (“UMass”).
All capitalized terms not defined herein are defined in the Exclusive License Agreement. All
parties that either have executed this Confidentiality Agreement or an undertaking thereto are
defined, collectively, as the “Parties.”

     WHEREAS, Alnylam may provide confidential and proprietary information identifying Targets and
Excluded Targets (the “Alnylam Target Information”) to UMass, Merck & Co., Inc. (“Merck”), or the
Gatekeeper, or any and all of them; and

     WHEREAS, Merck may provide confidential and proprietary information identifying proposed
Targets (the “Merck Target Information”) to the Gatekeeper; and

     WHEREAS, it is understood and agreed by the Parties that such disclosures are solely in
connection with the Exclusive License Agreement and not for any other purpose (the “Purposes”);

     NOW, THEREFORE, the Parties hereto agree as follows:

     1. Target Information. The Parties acknowledge and agree that the “Alnylam Target
Information” is and will remain Alnylam’s confidential, proprietary information; and that the
“Merck Target Information” is and will remain Merck’s confidential, proprietary information. The
Alnylam Target Information and the Merck Target Information are defined, collectively, as the
“Target Information.”

     2. Treatment of Target Information. The Party receiving Target Information not
otherwise known to it prior to disclosure is defined as the “Receiving Party.” The Party
disclosing Target Information is defined as the “Disclosing Party.” All Target Information
disclosed to the Receiving Party under the Exclusive License Agreement shall be governed by the
following provisions:

          a. Target Information may be used by solely in connection with the Purposes identified above.

          b. No Receiving Party shall disclose or permit disclosure of any Target Information of the
Disclosing Party to third parties or to employees of the Receiving Party, other than designated
directors, officers, employees and agents who are required to have the information in order to
perform the Parties’ authorized activities in connection with the Exclusive License Agreement.
Each Receiving Party has had or will have its designated directors, officers, employees and agents
who have access to Target Information of the Disclosing Party sign the undertaking annexed hereto
as Schedule 1, and, upon request, shall notify the Disclosing Party in writing of the names of each
person who has signed such agreements. Each Receiving Party agrees that it shall take all
reasonable and necessary measures to protect the secrecy of and avoid disclosure or unauthorized
use of Target

 

 

Information of the Disclosing party. Such measures shall include, but not be limited to, the
highest degree of care that the Receiving Party utilizes to protect its own information of a
similar nature, which shall be no less than reasonable care. Each Party agrees to notify the other
in writing of any actual or suspected misuse, misappropriation, or unauthorized disclosure of
Target Information of the Disclosing Party which may come to the Receiving Party’s attention and to
cooperate with the Disclosing Party to stop and prevent such activities.

          c. Unless otherwise agreed to by the Parties, Target Information disclosed under the Exclusive
License Agreement shall at all times remain, as between the Parties, the property of the Disclosing
Party. No license to use any trade secrets, copyrights, or other intellectual property rights is
granted by this Agreement.

          d. The Party providing the information shall determine the manner and form in which the Target
Information will be disclosed.

          e. In the event that the Receiving Party or any of its employees or agents become legally
compelled (by deposition, interrogatory, request for documents, subpoena, civil investigative
demand, court order, or similar process) to disclose any of the Target Information of the
Disclosing Party, that Party or person from whom such information is being sought shall provide the
other Party with prompt prior written notice of such requirement so that the other Party may seek a
protective order or other appropriate remedy and/or waive compliance with the terms of this
Agreement. In the event that such protective order or other remedy is not obtained, or the
Disclosing Party waives compliance with the provisions hereof, the Receiving Party and its
employees and agents agree to provide the Disclosing Party with information about what Target
Information will be disclosed and to furnish only that portion of the Target Information of the
Disclosing Party which is legally required to be furnished. The Receiving Party shall consult with
Disclosing Party and exercise in good faith all reasonable efforts to mutually agree with the
Disclosing Party regarding the nature, extent, and form of such production.

          f. No Receiving Party will disclose to any person not a Party to this Agreement or authorized
to review the Target information either the Target Information or the fact that the Receiving Party
is in possession of the Target Information.

          g. Public Information. The confidentiality provisions of this Agreement shall not apply to
any Target Information that is published or becomes generally known to the public other than
through the wrongful act of a Party hereto.

     3. Disclosure to UMass Pursuant to Section 2.2 of the Exclusive License Agreement. If
disclosure of Alnylam Target Information is made to UMass pursuant to Section 2.2 of the Exclusive
License Agreement, in addition to the other provisions of this Confidentiality Agreement, such
disclosure also shall be governed by the provisions of this Section 3 of this Confidentiality
Agreement:

          a. Prior to reviewing the Alnylam Target Information, the outside attorney designated by UMass
shall sign the undertaking attached as Schedule 1 hereto.

- 2 -

 

          b. The Alnylam Target Information may not be copied or reproduced by any means.

          c. The outside attorney may not disclose the Alnylam Target Information to anyone but may
simply confirm or deny that as of the Effective Date, there are [**] Excluded Targets.

     4. Disclosure to Gatekeeper Pursuant to Section 2.3 of the Exclusive License
Agreement. If disclosure of Target Information is made to the Gatekeeper pursuant to Section
2.3 of the Exclusive License Agreement, in addition to the other provisions of this Confidentiality
Agreement, such disclosure also shall be governed by the provisions of Section 4 of this
Confidentiality Agreement:

          a. Prior to receiving the Target Information, the Gatekeeper shall sign the undertaking
attached as Schedule 1 hereto.

          b. The Target Information may not be copied or reproduced by any means except as absolutely
necessary to transmit the Target Information to the Receiving Party and for the Gatekeeper to
comply with the requirements of Section 2.3 of the Exclusive License Agreement.

          c. Notwithstanding Section 6 hereof, the Gatekeeper may not assign this Agreement to anyone
without the written consent of all Parties.

     5. Term. The Target Information shall remain governed by the terms of this Agreement
during the Term of the Exclusive License Agreement.

     6. Assignment, Successors and Assigns. No Party may assign this Agreement without the
prior written consent of all Parties, except that Merck may assign it in connection with a merger,
acquisition, or sale of substantially all the assets of the business relating to the Tuschl I and
Tuschl II Patent Families. Nothing in this Agreement, express or implied, is intended to confer
upon any Party other than the Parties hereto any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

     7. Amendment. This Confidentiality Agreement may be amended, modified, canceled,
and/or waived only by a written instrument that expressly refers to this Confidentiality Agreement
and is executed subsequent to the effective date of this Agreement by duly authorized
representatives of each of the Parties hereto.

     8. Authority. Each of the undersigned represents that he or she has been duly
authorized to execute this Confidentiality Agreement on behalf of his or her respective clients or
entities.

     9. Damages Insufficient. Each Party hereto expressly agrees that due to the unique
nature of the Disclosing Party’s Target Information, monetary damages would be inadequate to
compensate the Disclosing Party for any breach by the Receiving Party of its covenants and
agreements set forth in this Agreement. Accordingly, each Party agrees and acknowledges that any
such violation or threatened violation shall cause irreparable injury to

- 3 -

 

the Disclosing Party and that, in addition to any other remedies that may be available, in
law, in equity or otherwise, the Disclosing Party shall be entitled to seek injunctive relief
against the threatened breach of this Agreement or the continuation of any such breach by the
Receiving Party, without the necessity of proving irreparable harm

     10. Choice of Law. This Confidentiality Agreement shall be governed by, construed,
and enforced in accordance with the laws of the Commonwealth of Massachusetts, without giving
effect to its choice of law provisions.

     11. Counterparts. This Confidentiality Agreement may be executed in counterparts,
each of which counterpart shall be original, but together shall constitute one and the same
instrument.

	 	 	 	 	 	 	 

	 	 	ALNYLAM PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Its:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 	 	UNIVERSITY OF MASSACHUSETTS	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Its:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 	 	MERCK & CO., INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Its:
	 	 

	 	 
	 

	 	 	 	 

	 	 

- 4 -

 

SCHEDULE 1

UNDERTAKING

     I, the undersigned, hereby agree and acknowledge that I am over the age of 18 and have read
the Confidentiality Agreement and the Exclusive License Agreement and agree to be bound by the
terms thereof. Specifically, I understand that by signing this Undertaking, I am bound by each of
the terms of the Confidentiality Agreement. I represent and warrant that I have had the
opportunity to consult with an attorney concerning the provisions of the Confidentiality Agreement
and my responsibilities and have either done so or have elected not to do so.

	 	 	 	 	 	 	 	 	 

	Dated:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 
	 	 

	 	 
	[NOTARY]
	 	 	 	 	 	 	 	 

 

 

Exhibit B to Exclusive License Agreement:

US Tuschl I Patent Family

 

 

	 	 	 
	Application No	 	Patent No
	09/821,832

	 	 
	10/255,568
	 	 
	11/474,738
	 	 
	11/474,919
	 	 
	11/474,930
	 	 
	11/474,932
	 	 
	11/880,355
	 	 
	11/880,464
	 	 
	12/897,744
	 	 
	12/897,749
	 	 
	12/897,754
	 	 
	12/897,756
	 	 
	12/897,759
	 	 
	12/897,740
	 	 
	13/008,636
	 	 
	60/193,594
	 	 
	60/265,232
	 	 

US TUSCHL I PATENT FAMILY

 

 

Exhibit C to Exclusive License Agreement:

US TUSCHL II PATENT FAMILY

	 	 	 	 	 
	U.S. Application No.	 	U.S. Patent No.
	10/433,050
	 	 	 	 
	10/832,248

	 	 	7,078,196	 
	10/832,257
	 	 	 	 
	10/832,432

	 	 	7,056,704	 
	11/142,865
	 	 	 	 
	11/142,866
	 	 	 	 
	11/634,138
	 	 	 	 
	11/634,129
	 	 	 	 
	12/260,443
	 	 	 	 
	12/537,602
	 	 	 	 
	12/537,632
	 	 	 	 
	12/591,829
	 	 	 	 
	12/683,070
	 	 	 	 
	12/683,081
	 	 	 	 
	12/794,071
	 	 	 	 

1

 

Exhibit C to Exclusive License Agreement:

US TUSCHL II PATENT FAMILY

	 	 	 
	U.S. Application No.	 	U.S. Patent No.
	12/819,444

	 	 
	12/834,311
	 	 
	12/835,086
	 	 
	12/838,786
	 	 
	12/879,300
	 	 
	12/897,374
	 	 

- 2 -exv10w4

Exhibit 10.4

AMENDMENT TO CO-EXCLUSIVE LICENSE AGREEMENT

     This Amendment to the Alnylam Co-Exclusive License Agreement is made as of March 14, 2011
(“Effective Date”), by and between Alnylam Pharmaceuticals, Inc. (“Alnylam”), on the one hand, and
Whitehead Institute for Biomedical Research (“Whitehead”), Massachusetts Institute of Technology
(“MIT”), and Max-Planck-Innovation GmbH (“MI”).

     This agreement is made with respect to the following recitals:

     WHEREAS, Alnylam and MI (at the time called Garching Innovation GmbH and referred to as GI in
the Alnylam Co-Exclusive License Agreement) are parties to the Alnylam Co-Exclusive License
Agreement;

     WHEREAS, Whitehead and MIT joined the Alnylam Co-Exclusive License Agreement on July 30, 2003;

     WHEREAS, the Alnylam Co-Exclusive License Agreement grants, among other things, a license to
the “MAX PLANCK PATENT RIGHTS” (as that term is defined in the Alnylam Co-Exclusive License
Agreement) to Alnylam, subject to the terms and conditions of the Alnylam Co-Exclusive License
Agreement;

     WHEREAS, pursuant to that certain Assignment Agreement made and entered into as of March 14,
2011, MIT and Whitehead have become co-owners of the MAX PLANCK PATENT RIGHTS in the US;

     WHEREAS, the purpose of this Amendment is to reflect that MIT and Whitehead have become
co-owners of the MAX PLANCK PATENT RIGHTS in the US and to amend the Alnylam Co-Exclusive License
Agreement accordingly;

     WHEREAS, MIT and Whitehead have the right to grant licenses under the MAX PLANCK PATENT RIGHTS
in the US;

     WHEREAS, Alnylam desires to obtain licenses with the right to grant sublicenses under the MAX
PLANCK PATENT RIGHTS in the US, and MIT and Whitehead desire to grant such licenses subject to the
conditions set forth herein;

     NOW, THEREFORE, Alnylam, on one hand, and each of MIT, Whitehead, and MI, on the other, hereby
agree as follows:

1. Definitions. The following words and phrases shall have the meanings set forth below
solely for purposes of this Amendment, including the recitals above.

     1.1. All capitalized terms not defined herein shall have the meaning set forth in the Alnylam
Co-Exclusive License Agreement.

     1.2. “Amendment” shall mean this Amendment to the Alnylam Co-Exclusive License Agreement.

 

 

     1.3. “Alnylam Co-Exclusive License Agreement” shall mean the Co-Exclusive License Agreement
originally executed on December 20, 2002, and subsequently amended, that grants therapeutic rights
to the JOINT PATENT RIGHTS and the MAX PLANCK PATENT RIGHTS to Alnylam subject to the terms and
conditions of that license agreement as amended.

2. Amendment to Alnylam Co-Exclusive License Agreement. The Parties agree that the Alnylam
co-Exclusive License Agreement shall be amended as follows:

     2.1. The second “WHEREAS” clause shall be amended to begin: “WHEREAS, MAX-PLANCK is the sole
owner of certain MAX PLANCK PATENT RIGHTS outside of the USA, and MAX-PLANCK, WHITEHEAD and M.I.T.
are the co-owners of certain MAX PLANCK PATENT RIGHTS in the USA...”

     2.2. The fifth “WHEREAS” clause shall be amended to state: “WHEREAS, WHITEHEAD and M.I.T. have
authorized GI to act as their agent for the purposes of licensing the JOINT PATENT RIGHTS and the
MAX PLANCK PATENT RIGHTS (including WHITEHEAD’s and M.I.T.’s co-ownership rights in the MAX PLANCK
PATENT RIGHTS in the USA) for therapeutic purposes, and therefore, this Agreement is binding on
each of WHITEHEAD and M.I.T.”

     2.3. Section 2.1 shall be amended to read as follows:

     2.1 License Grant. MIT, WHITEHEAD and GI grant to COMPANY for the TERM a
worldwide royalty-bearing co-exclusive license, with the right to grant sublicenses, under
the PATENT RIGHTS to develop, make, have made, use, sell and import LICENSED PRODUCTS in
the FIELD. MIT, WHITEHEAD and GI grant to COMPANY for the TERM a worldwide royalty-bearing
non-exclusive license, without the right to grant sublicenses, under the PATENT RIGHTS to
develop, make, have made, use, sell and import LICENSED PRODUCTS for all diagnostic uses
other than for purposes of therapeutic monitoring.

     2.4. The Heading of Section 6.3 shall be amended to read as follows: “6.3 Infringement of
JOINT PATENT RIGHTS.

     2.5. Section 6.3 shall be amended by adding the following at the beginning of the section,
immediately following the heading: “This Section shall govern infringement or possible infringement
of the JOINT PATENT RIGHTS.

     2.6. A new section shall be added after section 6.3 that reads as follows: “6.4 Infringement
of MAX PLANCK PATENT RIGHTS.”

     2.7. The following sections 6.4.1. through 6.4.5. shall be added:

     “6.4.1. Notice. Each Party shall notify the other Parties promptly in
writing of any infringement of any MAX PLANCK PATENT RIGHTS that becomes known to any of
them, including without limitation the receipt of any Paragraph IV notice letter under the
Drug Price Competition and Patent Term Restoration Act of 1984

- 2 -

 

(commonly referred to as the Hatch-Waxman Act). In no event shall such notice be
given more than 60 calendar days after learning of any infringement.

     6.4.2. Control of Patent Litigation. GI, M.I.T. and WHITEHEAD agree that
COMPANY may bring suit for infringement of any claim of the MAX PLANCK PATENT RIGHTS within
the FIELD, to enjoin infringement, to collect damages, profits and awards of whatever
nature recoverable for such infringement, to defend against any challenge to validity of
such patent, and to pursue any such litigation until a final judgment, from which no
further appeal may be taken and no further review may be sought. Alnylam shall reasonably
consult with M.I.T. and WHITEHEAD and keep them informed concerning developments in the US
Commercial Litigation.

          (a) M.I.T. and WHITEHEAD agree not to contest being joined as necessary parties by
motion or being named as co-plaintiffs upon reasonable prior notice, if necessary to
establish standing or subject matter jurisdiction, in any patent litigation brought in the
United States against a for-profit commercial entity (the “US Commercial Infringement
Litigation”), provided that the complaint satisfies all pleading obligations and the
requirements of Rule 11 of the Federal Rules of Civil Procedure. Subject to Section
6.4.2(b), COMPANY shall have sole and exclusive control over all decisions in any such US
Commercial Infringement Litigation except that COMPANY shall give good faith consideration
to the views of M.I.T. and WHITEHEAD concerning the selection of counsel for any US
Commercial Infringement Litigation or any settlement of any US Commercial Infringement
Litigation.

          (b) In the event there arises an actual or potential conflict of interest between
M.I.T. and/or WHITEHEAD on the one hand (the “Conflicted Party”), and Alnylam on the other
hand, with respect to the US Commercial Infringement Litigation such that representation of
the Conflicted Party by the counsel retained by COMPANY is inappropriate, the Conflicted
Party shall be entitled to select its own counsel, which counsel shall be paid for by the
Conflicted Party and not by COMPANY. Thereafter, COMPANY shall obtain the consent of the
Conflicted Party to settle the US Commercial Infringement Litigation, which consent shall
not be unreasonably withheld.

     6.4.3. Fees. Subject to Section 6.4.2(b) above, any and all fees, costs and
expenses incurred by COMPANY, M.I.T., WHITEHEAD, and/or GI including, without limitation,
attorney’s fees, court costs and disbursements, in connection with any action taken under
this Section 6.4 shall be paid by, and be the sole responsibility of, COMPANY.

     6.4.4. Cooperation. M.I.T., WHITEHEAD, and GI shall cooperate fully with
COMPANY in connection with any action under this Section 6.4 and agree to promptly provide
reasonable access to all necessary documents, information, and persons under their control,
and to render reasonable assistance in response to a request by COMPANY for such
assistance, all at the Company’s expense.

- 3 -

 

     6.4.5. Consent. None of M.I.T., WHITEHEAD, or GI shall be entitled to bring
a suit for infringement of any MAX PLANCK PATENT RIGHTS within the FIELD without the
express written consent of COMPANY, which COMPANY may withhold in its sole discretion.”

3. No Additional Rights. Nothing in this Amendment shall be construed to confer any rights
upon Alnylam by implication, estoppel, or otherwise as to any intellectual property rights,
including without limitation patents and patent applications, trademarks, copyrights and know-how,
of MIT or Whitehead other than the MAX PLANCK PATENT RIGHTS in the US, regardless of whether such
intellectual property rights shall be dominant or subordinate to any patent application or patent
in the MAX PLANCK PATENT RIGHTS in the US within the FIELD.

4. Miscellaneous Provisions.

     4.1. Non-Use of Owners’ Trademarks. Neither Alnylam nor its Affiliates and
Sublicensees shall use the name of “Massachusetts Institute of Technology,” “Whitehead Institute,”
or “University of Massachusetts,” or any variation, adaptation, or abbreviation thereof, or of any
of its trustees, officers, faculty, students, employees, or agents, or any trademark owned by any
of them, in any promotional material or other public announcement or disclosure, without the prior
written consent of the respective institution or in the case of an individual, the consent of that
individual. The foregoing notwithstanding, Alnylam may state generally that it is exclusively
licensed by MIT and/or Whitehead, under the MAX PLANCK PATENT RIGHTS in the US within the FIELD.

     4.2. Termination. MIT and Whitehead agree that this Amendment (including the license
granted under Section 2.1) is non-revocable and cannot be terminated under any circumstances,
except in the event of a termination of the Alnylam Co-Exclusive License Agreement pursuant to the
provisions of Article 11 of the Alnylam Co-Exclusive License Agreement, which termination shall
automatically terminate this Amendment.

     4.3. Notices. Any notices required or permitted under this Amendment and all
correspondence hereunder shall be in English and in writing, shall specifically refer to this
Amendment, and shall be sent by a method providing confirmation of delivery to the following
addresses or facsimile numbers of the parties:

     Notices as described above shall be provided to the following:

If to Max Planck:

Managing Director

Max Planck Innovation GmbH

Amalienstr. 33

80799 Munich

Germany

If to Alnylam:

- 4 -

 

Alnylam Pharmaceuticals, Inc.

300 Third Street

Cambridge, MA 02142

Attn: General Counsel

If to MIT:

Massachusetts Institute of Technology

77 Massachusetts Ave.

Cambridge, MA 02139-4307

Attn: Office of the General Counsel

If to WHITEHEAD:

Vice President

Whitehead Institute

Nine Cambridge Center

Cambridge, MA 02142-1493

     4.4. Governing Law. This Amendment, and all disputes arising out of or related to
such sections of this Amendment, or the performance, enforcement, breach or termination hereof, and
any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance
with section 12.2 (Governing Law) of the Alnylam Co-Exclusive License Agreement.

     4.5. Integration. This Amendment supersedes all prior written agreements and all
prior written and contemporaneous oral agreements with respect to the subject matter hereof, except
the Alnylam Co-Exclusive License Agreement, which, as amended by this Agreement, remains in full
force and effect.

     4.6. Amendment and Waiver. This Amendment may be amended, supplemented, or otherwise
modified only by means of a written instrument signed by all parties. Any waiver of any rights or
failure to act in a specific instance shall relate only to such instance and shall not be construed
as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

     4.7. Severability. Should one of the provisions of this Amendment be held void,
invalid or unenforceable, the remaining provisions of this Amendment will not cease to be
effective. The parties shall negotiate in good faith to replace such void, invalid or
unenforceable provision by a new provision which reflects, to the extent possible, the original
intent of the parties.

     4.8. Headings. All headings are for convenience only and shall not affect the meaning
of any provision of this Amendment.

- 5 -

 

     4.9. Dispute Resolution. The parties agree that any dispute or claim that arises
between or among them relating to or arising out of this Amendment, will be considered a dispute or
claim arising out of the Alnylam Co-Exclusive License Agreement and it shall be subject to the
procedures set forth in Section 12.3 of the Alnylam Co-Exclusive Agreement.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives.

	 	 	 	 	 	 	 

	ALNYLAM PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Barry Greene	 	 
	 

	 	 	 	 	 	 
	 

	 	Its:
	 	President and Chief Operating Officer	 	 
	 
	 	 	 	 	 	 
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	R. Gregory Morgan	 	 
	 

	 	 	 	 	 	 
	 

	 	Its:
	 	VP & General Counsel	 	 
	 
	 	 	 	 	 	 
	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Martin A. Mullins	 	 
	 

	 	 	 	 	 	 
	 

	 	Its:
	 	Vice President	 	 
	 
	 	 	 	 	 	 
	MAX PLANCK INNOVATION	 	 
	 

	 	By:
	 	/s/ Joe Gelies	 	 
	 

	 	 	 	 	 	 
	 

	 	Its:
	 	Managing Director	 	 

- 6 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]